Isabelle Billet - Dec 27, 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Chief Strategy and BD Officer
Signature
/s/Isabelle Billet
Stock symbol
AXGN
Transactions as of
Dec 27, 2022
Transactions value $
-$3,087
Form type
4
Date filed
12/29/2022, 07:52 PM
Previous filing
Jul 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $0 +1.15K +4.74% $0.00 25.4K Dec 27, 2022 Direct F1
transaction AXGN Common Stock Tax liability -$3.09K -327 -1.29% $9.44 25.1K Dec 27, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Restricted Stock Units Options Exercise $0 +1.15K $0.00* 0 Dec 27, 2022 Common Stock 1.15K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This reflects the number of restricted stock units that vested on December 27, 2022.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4 All shares of AxoGen Inc. common stock underlying the restricted stock units vested on December 27, 2022 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on December 27, 2020 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter.